Dermatology · Falls Church, VA
NPI
1801913561
Since 2007
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
201 N Washington St
Falls Church, VA, 22046
Phone (703) 531-1616
Groups this clinician bills Medicare through
Medicare paid, 2024
$3,796
76 services
Medicare patients, 2024
33
Average age 75
Drug cost, 2024
$574K
1,193 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Mark Naftanel prescribed most often to Medicare patients was Clobetasol Propionate, with 158 prescriptions and refills. In total Mark Naftanel wrote 1,193 Medicare prescriptions that cost $574K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-05-27.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Clobetasol Propionate Generic | 158 | 172 | 99 | $4,629 |
| Triamcinolone Acetonide Generic | 127 | 161 | 88 | $2,837 |
| Tacrolimus Generic | 112 | 117 | 69 | $8,580 |
| Fluorouracil Generic | 87 | 87 | 83 | $3,921 |
| Clindamycin Phosphate Generic | 74 | 78 | 39 | $2,867 |
| Retin-A Tretinoin | 59 | 66 | 34 | $2,651 |
| Fluocinonide Generic | 49 | 49 | 30 | $766 |
| Ketoconazole Generic | 44 | 55 | 19 | $816 |
| Metronidazole Generic | 38 | 40 | 20 | $734 |
| Methotrexate Methotrexate Sodium | 34 | 85 | 11 | $478 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 31 | 36 | Under 11 | $136K |
| Dupixent Pen Dupilumab | 30 | 30 | Under 11 | $116K |
| Otezla Apremilast | 25 | 25 | Under 11 | $98K |
| Calcipotriene Generic | 25 | 25 | 24 | $2,835 |
| Amjevita(Cf) Autoinjector Adalimumab-Atto | 24 | 26 | Under 11 | $26K |
Brand drugs: 213 claims; generic drugs: 980 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Mark Naftanel were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.